



## Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2025

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at **4:20 PM EDT on Thursday, June 5, 2025**, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.

A live webcast link for the presentation will be available at <https://investors.werewolftx.com/news-and-events/events>. An archived replay will be available for approximately 90 days following the event.

### **About Werewolf Therapeutics:**

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company's most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit [www.werewolftx.com](http://www.werewolftx.com).

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Investor Contact Dan Ferry LifeSci Advisors 617.430.7576 [daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com) Media Contact: Amanda Sellers Deerfield Group 301.332.5574 [amanda.sellers@deerfieldgroup.com](mailto:amanda.sellers@deerfieldgroup.com) Company Contact: Timothy Trost Chief Financial Officer Werewolf Therapeutics [ttrost@werewolftx.com](mailto:ttrost@werewolftx.com)